Main trends of immune effects triggered by nanomedicines in preclinical studies

Abstract

The application of nanotechnology to emerging medicinal products is a crucial parameter for the implementation of personalized medicine. For example, sophisticated drug delivery systems can target the diseased tissue by recognizing patient-specific biomarkers while carrying pharmacologically active molecules. However, such nanomedicines can be recognized by the immune system as foreign triggering unexpected biological reactions. The anticipation of the immunogenic potential of emerging nanotechnology-based products in the preclinical phase is challenging due to high interspecies variations between the immune systems of laboratory animals and humans. A close monitoring of the scientific literature is required to better understand the relationship between various immune reactions and the diversity of nanomedicines currently in the development pipeline. We have reviewed the most frequent immune reactions induced by the nanomaterials in vivo and have identified the main effects triggered by lipid-based, polymer-based and inorganic nanoparticles, as the main categories of nanomaterials used in medicine. According to our results, almost 50% of the investigated nanomaterials induced effects related to the activation of the immune system. Among them, complement activation-related hypersensitivity reactions and activation of adaptive immune response were the most frequent effects reported for the lipid-based nanoparticles. However, many of these effects are not or are only partially covered by the current regulatory framework applicable for nanomedicines. In addition, we extracted the most relevant nanospecific properties responsible for the observed biological effects. Our analysis led to identification of the most prevalent measurement endpoints relevant for the assessment of the immunotoxic potential of the nanotechnology-based products and will support the smooth and safe translation of the new formulations to clinical applications.

EGCG Mediated Targeting of Deregulated Signaling Pathways and Non-Coding RNAs in Different Cancers: Focus on JAK/STAT, Wnt/β-Catenin, TGF/SMAD, NOTCH, SHH/GLI, and TRAIL Mediated Signaling Pathways

“…For instance, transition metal oxide NPs have been found to increase oxidative stress, disturb calcium homeostasis, and deregulate cell cycle [102]. The activation of the immune system, specifically macrophage activation and cytokine release has been also reported [103]. Thus, lipid-based NPs show higher level of biocompatibility and bioavailability, emerging as the best candidates for pharmaceutical and clinical applications.…”

Precision nanomedicine in atherosclerosis therapy: how far are we from reality?

“…There are several reviews detailing how nanoparticles with various physiochemical properties interact with the immune system [75][76][77]. In a recent review by Halamoda-Kenzaoui [78], 61% of the reported lipid-based nanoparticles showed an effect on the immune system, mainly the activation of the complement system. The complement system is a critical component of the innate immunity, generating immediate unspecific defense reactions against pathogenic infections.…”

“…The complement system can be activated via 3 distinct pathways (classical, lectin, and alternative) that converge to generate the same set of effector molecules at the third component of complement (C3) [79]. The cascade of reactions can lead to (1) proinflammatory process with the release of anaphylatoxins, (2) opsonization of vesicles, which in turn, triggers their rapid clearance, and (3) membrane lysis [78]. All 3 pathways can be activated in contact with NPs, leading to inflammatory process or hypersensitivity reactions called complement activation-related pseudoallergy (CARPA).…”

“…Although CAPRA resolves most of the time after stopping the infusion, the reaction may be life-threatening or fatal in a minority of patients (≤ 0.01%) [81,82]. Hence, it is critical to wholly evaluate the impact of nanoparticles on their cytotoxicity and in vivo CAPRA response before further investigation in human [75,76,78].…”

Assessing the Safety of Nanomedicines: A Mini Review

“…Nanoparticles (NPs) are being applied across various disciplines of medicine due to their design, properties, and application in personalized medicine. 1 They started to emerge on the market over a decade ago and their use has increased exponentially. 2 They are characterized by their advantageously tiny size, with a nanometer being one-millionth of a millimeter and *100,000 smaller than the diameter of a human hair.…”